Drug intelligence / Profile preview

Shugan Zhi Tablet

Development stage: Unknown
Lead developer: Shanghai Fang Xin Pharmaceutical Technology
Administration: Oral

Overview

Shugan Zhi Tablet is a traditional Chinese medicine (TCM) developed by Shanghai Fangxin Pharmaceutical Technology for the treatment of nonalcoholic fatty liver disease (NAFLD). The drug is specifically targeted at patients exhibiting the TCM syndrome of liver depression and spleen deficiency with damp-heat. It is formulated as an oral tablet and has undergone Phase 2 clinical evaluation in China (CTR20180031) to investigate its efficacy in reducing liver fat and improving metabolic health in adults with simple fatty liver.

Brand names: Shugan Zhi Tablet
Other names: Shugan Zhi Pian

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)AMPK (Adenosine monophosphate–activated protein kinase)RELA (Nuclear Factor Kappa B Subunit p65)

Beyond the preview

Go deeper on Shugan Zhi Tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shugan Zhi Tablet.

Explore the full profile